Having trouble accessing articles? Reset your cache.

ZymoGenetics, Bristol-Myers deal

Bristol-Myers plans to acquire partner ZymoGenetics in a tender offer at $9.75 per share, or about $885 million in cash. The price is an 84%

Read the full 258 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE